ストックスクリーナーアプリを入手
39.61
5.18%
1.95
前日終値:
$37.66
開ける：
$33.375
24時間の取引高:
1.53M
Relative Volume:
2.60
時価総額：
$1.10B
収益：
$17.16M
当期純損益:
$-163.62M
株価収益率:
-6.5148
EPS:
-6.08
ネットキャッシュフロー:
$-121.61M
1週間 パフォーマンス:
+17.12%
1か月 パフォーマンス:
+16.12%
6か月 パフォーマンス:
+90.39%
1年 パフォーマンス:
+87.10%
1日の値動き範囲:
$33.10
$40.13
1週間の範囲:
$33.01
$40.13
52週間の値動き範囲:
$12.21
$40.96
Anaptysbio Inc Stock (ANAB) Company Profile
名前
Anaptysbio Inc
セクター
電話
858-362-6295
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
39.61 | 1.04B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-06-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-07-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-19 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Wells Fargo | Overweight |
| 2024-03-12 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-02-26 | 開始されました | BTIG Research | Buy |
| 2024-02-21 | 開始されました | Stifel | Buy |
| 2024-02-16 | 開始されました | Piper Sandler | Overweight |
| 2023-05-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-13 | ダウングレード | Truist | Buy → Hold |
| 2022-09-01 | 開始されました | Raymond James | Outperform |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-03-16 | アップグレード | Truist | Hold → Buy |
| 2021-03-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-03-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-02-11 | アップグレード | JP Morgan | Underweight → Overweight |
| 2020-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-10-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2019-11-08 | ダウングレード | Jefferies | Buy → Hold |
| 2019-11-08 | ダウングレード | SunTrust | Buy → Hold |
| 2019-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-21 | 開始されました | JP Morgan | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-04-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 繰り返されました | Stifel | Buy |
| 2018-03-06 | 繰り返されました | Stifel | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2018-01-23 | 繰り返されました | Credit Suisse | Outperform |
| 2017-11-15 | 開始されました | SunTrust | Buy |
| 2017-11-09 | 開始されました | Jefferies | Buy |
| 2017-10-11 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Anaptysbio Inc (ANAB) 最新ニュース
Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat
AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in
AnaptysBio (NASDAQ:ANAB) Shares Gap DownTime to Sell? - MarketBeat
AnaptysBio sets $100M stock repurchase plan - MSN
AnaptysBio expands stock repurchase plan by $100 million - Investing.com Nigeria
Tesaro and AnaptysBio Enter Legal Battle Over Suspected Breach in Contract - PharmExec.com
European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand - MarketScreener
GSK, Anaptysbio sue each other over Jemperli revenue - BioPharma Dive
AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
Legal Battle Puts AnaptysBio's Jemperli Royalties At Risk - Finimize
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement By Investing.com - Investing.com South Africa
AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement - GuruFocus
ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - Stocktwits
AnaptysBio Expands Stock Repurchase Plan by $100M - TipRanks
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement - Investing.com India
GSK and AnaptysBio Lock Horns Over Jemperli Deal - Citeline News & Insights
AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK - GuruFocus
GSK subsidiary TESARO files lawsuit against AnaptysBio over Jemperli license - Investing.com
[8-K] ANAPTYSBIO, INC Reports Material Event | ANAB SEC FilingForm 8-K - Stock Titan
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
AnaptysBio stock falls after filing lawsuit against GSK unit - Investing.com
AnaptysBio drops after litigation with GSK unit (ANAB:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
GSK, AnaptysBio Sue Each Other Over Cancer Drug License - The Wall Street Journal
GSK unit and AnaptysBio trade lawsuits over Jemperli - pharmaphorum
AnaptysBio (ANAB) Expands Stock Buyback Program to $100 Million - GuruFocus
AnaptysBio Launches $100 Million Share Buyback Program - MarketScreener
AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal - MarketScreener
AnaptysBio Sues Tesaro, GSK Over Alleged Breaches of Jemperli License Deal - MarketScreener
Will AnaptysBio Inc. (AN6) stock beat international competition2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
GSK Faces Legal Challenge Over Alleged Interference with Anaptys - GuruFocus
AnaptysBio Approves Amended $100 Mln Stock Repurchase Plan - Nasdaq
GSK files suit against AnaptysBio over licensing rights - Vox Markets
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - The Manila Times
AnaptysBio (Nasdaq: ANAB) Announces $100M Stock Buyback Plan Through 2026 - Stock Titan
AnaptysBio files lawsuit against Tesaro over collaboration breach - StreetInsider
GSK’s TESARO Initiates Litigation Against AnaptysBio - AskTraders.com
GSK's Tesaro Sues AnaptysBio Over Jemperli License Breach - MarketScreener
TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement - Nasdaq
GSK arm Tesaro initiates litigation against AnaptysBio - Medical Dialogues
GSK Starts Litigation Against AnaptysBio Inc - MarketWatch
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute By Investing.com - Investing.com Australia
GSK unit sues AnaptysBio in row over Jemperli rights - Proactive financial news
TESARO Initiates Legal Action Against AnaptysBio Over Jemperli License - TipRanks
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute - Investing.com
REGGSK PLCInitiation of litigation against AnaptysBio Inc - TradingView
GSK subsidiary Tesaro sues AnaptysBio over Jemperli license breach - MarketScreener
GSK (GSK) Pursues Legal Action Against AnaptysBio Over License D - GuruFocus
TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc. - GSK
AnaptysBio, Inc. authorizes a Buyback Plan. - MarketScreener
Savant Capital LLC Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Inc (ANAB) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):